Home LiteratureArticle Details
PMID: 21541702 Published · ppublish English

Evidence for a link between TNFRSF11A and risk of breast cancer.

Breast cancer research and treatment ·Vol. 129 ·No. 3 ·2012-09-13

Bonifaci Núria, Palafox Marta, Pellegrini Pasquale, Osorio Ana, Benítez Javier, Peterlongo Paolo, Manoukian Siranoush, Peissel Bernard, Zaffaroni Daniela, Roversi Gaia, Barile Monica, Viel Alessandra, Mariette Frederique, Bernard Loris, Radice Paolo, Kaufman Bella, Laitman Yael, Milgrom Roni, Friedman Eitan, Sáez María E, Climent Fina, Soler María Teresa, Diez Orland, Balmaña Judith, Lasa Adriana, Ramón y Cajal Teresa, Miramar María-Dolores, de la Hoya Miguel, Pérez-Segura Pedro, Caldés Trinidad, Moreno Víctor, Urruticoechea Ander, Brunet Joan, Lázaro Conxi, Blanco Ignacio, Pujana Miguel Angel, González-Suárez Eva

Abstract

Intracellular signaling mediated by the receptor activator of nuclear factor-κB [Rank, encoded by the tumor necrosis factor receptor superfamily, member 11a (Tnfrsf11a) gene] is fundamental for mammary gland development in mice, regulating the expansion of stem and progenitor cell compartments. Conversely, Rank overexpression in mice promotes abnormal proliferation and impairs differentiation, leading to an increased incidence of tumorigenesis. Here, we show that a common genetic variant near the 5'-end of TNFRSF11A, rs7226991, is associated with breast cancer risk in the general population and among carriers of mutations in the breast cancer 2, early onset (BRCA2) gene. Akin to the results of the Cancer and Genetics Markers of Susceptibility initiative, combined analysis of rs7226991 in two Spanish case-control studies (1,365 controls and 1,323 cases in total) revealed a significant association with risk: odds ratio (OR) = 0.88, 95% confidence interval (CI) 0.78-0.98, P (trend) = 0.025. Subsequent examination of BRCA1 (n = 1,017) and BRCA2 (n = 885) mutation carriers revealed a consistent association in the latter group: weighted hazard ratio ((w)HR) = 0.70; 95% CI 0.55-0.88; and P (trend) = 0.003; compared to BRCA1 mutation carriers, (w)HR = 0.91; 95% CI 0.76-1.10; and P (trend) = 0.33. The results of this study need to be replicated in other populations and with larger numbers of BRCA1/2 mutation carriers.

Article Info
Journal
Breast cancer research and treatment
Abbr.
Breast Cancer Res Treat
Published
2012-09-13
Indexed
2011-09-08
Updated
2011-09-08
Language
English
Country/Region
Netherlands
NLM ID
8111104
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com